THIS MONTH’S ISSUE

Read, save, and print articles from the current issue

ARTICLES

Chronological index
2013–2017

PRODUCT GUIDES

Compare all instruments
and software systems

DEPARTMENTS

Chronological index
2013–2017

WEBINARS

Register Now and
On Demand

Home » Top news

BloodCenter of Wisconsin’s VWF activity test

April 21, 2017BloodCenter of Wisconsin, part of Versiti, announced the launch of a new assay that will more accurately measure von Willebrand factor activity. The VWF GPIbM Activity test, which detects qualitative von Willebrand factor defects, uses patented technology previously not used in the United States. Precise measurement of VWF platelet binding activity is critical for making an accurate diagnosis of von Willebrand disease in patients.

BloodCenter of Wisconsin is the first organization to make this test available in the United States in a clinical laboratory setting, the company said. Utilizing VWF GPIbM Activity, practicing hematologists can be confident the results reflect the clinical scenario of the patient.

“As a physician caring for individuals with inherited bleeding disorders, this development is an exciting advancement in von Willebrand disease diagnostics,” Johnathan Roberts, MD, associate medical director, Bleeding and Clotting Disorders Institute of Peoria, Ill., said in a company statement. “This assay will reduce some of the diagnostic challenges in caring for individuals with von Willebrand disease.”

More top news

Print Friendly, PDF & Email
Tags:

X